These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36696931)

  • 1. Advancements and future trends of immunotherapy in light-chain amyloidosis.
    Mahadevia H; Ponvilawan B; Sharma P; Al-Obaidi A; Qasim H; Koyi J; Anwer F; Raza S
    Crit Rev Oncol Hematol; 2023 Mar; 183():103917. PubMed ID: 36696931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and Emerging Immunotherapies for Systemic AL Amyloidosis.
    Moreno V; Saba L; Tama-Shekan S; Chaulagain CP
    Discov Med; 2024 Sep; 36(188):1761-1771. PubMed ID: 39327239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daratumumab for the treatment of AL amyloidosis.
    Sidiqi MH; Gertz MA
    Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy in AL Amyloidosis.
    Zhang Y; Comenzo RL
    Curr Treat Options Oncol; 2022 Jul; 23(7):1059-1071. PubMed ID: 35635625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
    Popkova T; Hajek R; Jelinek T
    Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation following simultaneous liver and kidney transplantation in severe amyloid light chain amyloidosis associated with multiple myeloma: a case report.
    Al-Zoairy R; Viveiros A; Zoller H; Schneeberger S; Oberhuber G; Gunsilius E; Tilg H; Wolf D; Rudzki JD
    J Med Case Rep; 2020 Oct; 14(1):201. PubMed ID: 33099313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacist's review of the treatment of systemic light chain amyloidosis.
    Hughes DM; Staron A; Sanchorawala V
    J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
    Palladini G; Milani P; Malavasi F; Merlini G
    Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
    Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
    Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
    Chen W; Ren G; Zuo K; Huang X
    Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atraumatic Splenic Rupture Due to Ectopic Extramedullary Hematopoiesis after Autologous Stem Cell Transplantation in a Patient with AL Amyloidosis.
    Sato S; Tamai Y; Okada S; Kannbe E; Takeda K; Tanaka E
    Intern Med; 2018 Feb; 57(3):399-402. PubMed ID: 29093392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic AL Amyloidosis without Significant Light Chain Elevation in a Patient Treated with CyBorD Plus Daratumumab.
    Rybinski B; Kocoglu M
    Am J Case Rep; 2021 Aug; 22():e933241. PubMed ID: 34421115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for the treatment of light chain amyloidosis.
    Chakraborty R; Lentzsch S
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):299-317. PubMed ID: 32731778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis.
    Nuvolone M; Basset M; Palladini G
    Expert Opin Drug Saf; 2021 Apr; 20(4):411-426. PubMed ID: 33583294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel monoclonal antibodies: A really specific therapy for light chain amyloidosis.
    Del Giudice ML; Galimberti S; Buda G
    Hematol Oncol; 2024 May; 42(3):e3270. PubMed ID: 38590272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac Amyloidosis Treatment.
    Stern LK; Patel J
    Methodist Debakey Cardiovasc J; 2022; 18(2):59-72. PubMed ID: 35414852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.